CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's 2024 earnings exceeded estimates, with 25% revenue growth and strong performance in diabetes, obesity, and rare disease segments. The market overreacted to CagriSema trial results ...

Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...

During the relevant period, Novo Nordisk was conducting its highly anticipated Phase 3 study, REDEFINE-1, for CagriSema, an investigational drug developed for the treatment of obesity and type 2 ...

Also Read: Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's ...

Novo Nordisk began this year recovering from the disappointing trial results of its next-generation weight loss drug CagriSema. After a late-stage trial slightly missed expectations, the company ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...